Home LiteratureArticle Details
PMID: 14645467 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Mechanism of toxicity in rotenone models of Parkinson's disease.

Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT

Abstract

Exposure of rats to the pesticide and complex I inhibitor rotenone reproduces features of Parkinson's disease, including selective nigrostriatal dopaminergic degeneration and alpha-synuclein-positive cytoplasmic inclusions (Betarbet et al., 2000; Sherer et al., 2003). Here, we examined mechanisms of rotenone toxicity using three model systems. In SK-N-MC human neuroblastoma cells, rotenone (10 nm to 1 microm) caused dose-dependent ATP depletion, oxidative damage, and death. To determine the molecular site of action of rotenone, cells were transfected with the rotenone-insensitive single-subunit NADH dehydrogenase of Saccharomyces cerevisiae (NDI1), which incorporates into the mammalian ETC and acts as a "replacement" for endogenous complex I. In response to rotenone, NDI1-transfected cells did not show mitochondrial impairment, oxidative damage, or death, demonstrating that these effects of rotenone were caused by specific interactions at complex I. Although rotenone caused modest ATP depletion, equivalent ATP loss induced by 2-deoxyglucose was without toxicity, arguing that bioenergetic defects were not responsible for cell death. In contrast, reducing oxidative damage with antioxidants, or by NDI1 transfection, blocked cell death. To determine the relevance of rotenone-induced oxidative damage to dopaminergic neuronal death, we used a chronic midbrain slice culture model. In this system, rotenone caused oxidative damage and dopaminergic neuronal loss, effects blocked by alpha-tocopherol. Finally, brains from rotenone-treated animals demonstrated oxidative damage, most notably in midbrain and olfactory bulb, dopaminergic regions affected by Parkinson's disease. These results, using three models of increasing complexity, demonstrate the involvement of oxidative damage in rotenone toxicity and support the evaluation of antioxidant therapies for Parkinson's disease.

MeSH Terms
Adenosine Triphosphate/deficiency,metabolism Animals Antioxidants/pharmacology Cell Death/drug effects Cell Line Disease Models, Animal Dopamine/metabolism Dose-Response Relationship, Drug Electron Transport Complex I/antagonists & inhibitors Enzyme Inhibitors/toxicity Humans In Vitro Techniques Mesencephalon/drug effects,metabolism,pathology Neuroblastoma/drug therapy,metabolism,pathology Neurons/drug effects,metabolism,pathology Neuroprotective Agents/pharmacology Olfactory Bulb/drug effects,pathology Oxidative Stress/drug effects Parkinsonian Disorders/chemically induced,pathology,physiopathology Rats Rats, Inbred Lew Rotenone/toxicity Time
Chemicals
Antioxidants Enzyme Inhibitors Neuroprotective Agents Rotenone Adenosine Triphosphate Electron Transport Complex I Dopamine
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Sherer Todd B
Center for Neurodegenerative Disease, Emory University, Atlanta, Georgia 30322, USA. [email protected]
Betarbet Ranjita
Testa Claudia M
Seo Byoung Boo
Richardson Jason R
Kim Jin Ho
Miller Gary W
Yagi Takao
Matsuno-Yagi Akemi
Greenamyre J Timothy
References (49)
49 references, click to expand
  1. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia.
    Biochim Biophys Acta. 1999 Feb 9;1410(2):159-70 PMID: 10076024
  2. Novel free radical spin traps protect against malonate and MPTP neurotoxicity.
    Exp Neurol. 1999 May;157(1):120-6 PMID: 10222114
  3. Titrating the effects of mitochondrial complex I impairment in the cell physiology.
    J Biol Chem. 1999 Jun 4;274(23):16188-97 PMID: 10347173
  4. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation.
    Neuroscience. 2000;97(2):279-84 PMID: 10799759
  5. 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism.
    J Neural Transm (Vienna). 2000;107(3):281-93 PMID: 10821437
  6. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease.
    J Biol Chem. 2000 Aug 25;275(34):26096-101 PMID: 10846169
  7. alpha-synuclein promotes mitochondrial deficit and oxidative stress.
    Am J Pathol. 2000 Aug;157(2):401-10 PMID: 10934145
  8. Use of the NADH-quinone oxidoreductase (NDI1) gene of Saccharomyces cerevisiae as a possible cure for complex I defects in human cells.
    J Biol Chem. 2000 Dec 1;275(48):37774-8 PMID: 10982813
  9. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.
    Science. 2000 Nov 3;290(5493):985-9 PMID: 11062131
  10. Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein.
    J Neurochem. 2000 Dec;75(6):2546-54 PMID: 11080208
  11. Chronic systemic pesticide exposure reproduces features of Parkinson's disease.
    Nat Neurosci. 2000 Dec;3(12):1301-6 PMID: 11100151
  12. Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence.
    Brain Res. 2001 Feb 16;892(1):211-7 PMID: 11172767
  13. Lack of complex I activity in human cells carrying a mutation in MtDNA-encoded ND4 subunit is corrected by the Saccharomyces cerevisiae NADH-quinone oxidoreductase (NDI1) gene.
    J Biol Chem. 2001 Oct 19;276(42):38808-13 PMID: 11479321
  14. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors.
    J Biol Chem. 2002 Feb 15;277(7):5411-7 PMID: 11724769
  15. Environment, mitochondria, and Parkinson's disease.
    Neuroscientist. 2002 Jun;8(3):192-7 PMID: 12061498
  16. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
    Neurobiol Dis. 2002 Jul;10(2):119-27 PMID: 12127150
  17. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.
    J Neurosci. 2002 Aug 15;22(16):7006-15 PMID: 12177198
  18. Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state.
    Biochem J. 2002 Dec 1;368(Pt 2):545-53 PMID: 12180906
  19. A single-subunit NADH-quinone oxidoreductase renders resistance to mammalian nerve cells against complex I inhibition.
    Mol Ther. 2002 Sep;6(3):336-41 PMID: 12231169
  20. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
    Arch Neurol. 2002 Oct;59(10):1541-50 PMID: 12374491
  21. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats.
    Behav Brain Res. 2002 Oct 17;136(1):317-24 PMID: 12385818
  22. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.
    Exp Neurol. 2003 Jan;179(1):9-16 PMID: 12504863
  23. The role of oxidative stress in paraquat-induced neurotoxicity in rats: protection by non peptidyl superoxide dismutase mimetic.
    Neurosci Lett. 2003 Jan 2;335(3):163-6 PMID: 12531458
  24. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis.
    Biochemistry. 2003 Jan 28;42(3):829-37 PMID: 12534296
  25. Vitamin E prevents oxidation of antiapoptotic proteins in neuronal cells.
    Proteomics. 2003 Jan;3(1):73-7 PMID: 12548636
  26. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats.
    J Neurochem. 2003 Feb;84(3):491-502 PMID: 12558969
  27. Nicotine protects rat brain mitochondria against experimental injuries.
    Neuropharmacology. 2003 Apr;44(5):642-52 PMID: 12668050
  28. A simple method for organotypic cultures of nervous tissue.
    J Neurosci Methods. 1991 Apr;37(2):173-82 PMID: 1715499
  29. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease.
    Biochem Biophys Res Commun. 1989 Sep 29;163(3):1450-5 PMID: 2551290
  30. Abnormalities of the electron transport chain in idiopathic Parkinson's disease.
    Ann Neurol. 1989 Dec;26(6):719-23 PMID: 2557792
  31. Mitochondrial complex I deficiency in Parkinson's disease.
    Lancet. 1989 Jun 3;1(8649):1269 PMID: 2566813
  32. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
    Life Sci. 1985 Jul 1;36(26):2503-8 PMID: 2861548
  33. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease.
    J Neurochem. 1989 Feb;52(2):381-9 PMID: 2911023
  34. Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione.
    J Pharmacol Exp Ther. 1988 Nov;247(2):502-7 PMID: 3183949
  35. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates.
    J Neurochem. 1981 Feb;36(2):589-93 PMID: 7463078
  36. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease.
    Ann Neurol. 1995 Jun;37(6):714-22 PMID: 7778844
  37. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease.
    Neurology. 1993 Nov;43(11):2258-62 PMID: 8232939
  38. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.
    N Engl J Med. 1993 Jan 21;328(3):176-83 PMID: 8417384
  39. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
    Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2696-701 PMID: 8610103
  40. Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease.
    Adv Exp Med Biol. 1996;387:97-106 PMID: 8794199
  41. Alpha-synuclein in Lewy bodies.
    Nature. 1997 Aug 28;388(6645):839-40 PMID: 9278044
  42. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease.
    J Neurochem. 1997 Sep;69(3):1326-9 PMID: 9282961
  43. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay.
    J Neurochem. 1998 Jan;70(1):268-75 PMID: 9422371
  44. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease.
    Biochim Biophys Acta. 1997 Nov 28;1362(1):77-86 PMID: 9434102
  45. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
    J Neural Transm (Vienna). 1997;104(6-7):661-77 PMID: 9444566
  46. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living.
    Neurology. 1998 May;50(5):1346-50 PMID: 9595985
  47. Oxidative mechanisms in nigral cell death in Parkinson's disease.
    Mov Disord. 1998;13 Suppl 1:24-34 PMID: 9613715
  48. Parkinson's disease, pesticides, and glutathione transferase polymorphisms.
    Lancet. 1998 Oct 24;352(9137):1344-6 PMID: 9802272
  49. Interaction of alpha-phenyl-N-tert-butyl nitrone and alternative electron acceptors with complex I indicates a substrate reduction site upstream from the rotenone binding site.
    J Neurochem. 1998 Dec;71(6):2549-57 PMID: 9832155
Article Info
Journal
The Journal of neuroscience : the official journal of the Society for Neuroscience
Abbr.
J Neurosci
ISSN
1529-2401
Published
2003-11-26
Pages
10756-64
Language
English
Region
United States
NLM ID
8102140
PMCID
PMC6740985
Subset
IM
Grants
NINDS NIH HHS · T32 NS007480 · United States
NINDS NIH HHS · R21 NS043776 · United States
NINDS NIH HHS · T32NS07480 · United States
NIDDK NIH HHS · R01 DK053244 · United States
NINDS NIH HHS · NS38899 · United States
NIEHS NIH HHS · ES012068 · United States
NIEHS NIH HHS · U54 ES012068 · United States
NINDS NIH HHS · NS43776 · United States
NIDDK NIH HHS · DK53244 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]